Citius Pharmaceuticals Inc (CTXR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.69M
Last updated: Nov 17, 2026 at 4:15 PM ET
Citius Pharmaceuticals Inc (CTXR) Statistics
Citius Pharmaceuticals (CTXR) has a market cap of $14.69M and an enterprise value of $4.09M. Revenue grew 4456.78% over the last 12 months from the 12 months before. It kept -818.65% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 72.14% below the market cap, as cash exceeds debt.
| Market Cap | $14.69M |
|---|---|
| Enterprise Value | $4.09M |
| Latest price (Nov 17, 2026) | $0.52 |
Key Dates
The next earnings report is expected on Dec 21, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Dec 21, 2026 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | September |
Valuation Ratios
Sales and book value multiples are 1.9x and 0.2x.
| P/S Ratio | 1.9x |
|---|---|
| Forward P/S | 0.7x |
| P/B Ratio | 0.2x |
| P/TBV Ratio | 0.2x |
Price Statistics
The stock is down 47.01% over 52 weeks and trades at its 50-day average.
| Beta (1Y) | 1.92 |
|---|---|
| 52-Week Change | -47.01% |
| 1-Month Change | +21.27% |
| 3-Month Change | -18.62% |
| 6-Month Change | -6.39% |
| 5-Year Change | -98.88% |
| Total Return (1Y) | -47.01% |
| Total Return (3Y CAGR) | -70.05% |
| Total Return (5Y CAGR) | -58.55% |
| Max Drawdown (1Y) | -74.25% |
| Max Drawdown (3Y) | -98.56% |
| Sharpe Ratio (1Y) | -0.68 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $0.52 |
| 200-Day Average | $0.64 |
| 52-Week Range | $0.37 to $1.54 |
| RSI (14 Days) | 50.5 |
| Average Volume (20 Days) | 289.32K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.84x current liabilities, and total debt is 0.10x shareholder equity.
| Current Ratio | 0.84x |
|---|---|
| Quick Ratio | 0.40x |
| Debt / Equity | 0.10x |
| Interest Coverage | -119.35x |
Returns and Efficiency
Return on invested capital is -84.31% over the last 12 months, against a 5-year average of -39.80%.
| Return on Equity (ROE) | -87.32% |
|---|---|
| Return on Assets (ROA) | -40.89% |
| Return on Invested Capital (ROIC) | -84.31% |
| ROE (5Y Average) | -40.22% |
| ROA (5Y Average) | -28.25% |
| ROIC (5Y Average) | -39.80% |
| Asset Turnover | 0.05x |
| Inventory Turnover | 0.07x |
| Receivables Turnover | 8.05x |
| Cash Conversion Cycle | 3286 days |
Scores
CTXR has an Altman Z-Score of -4.05, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.05 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $7.11M over the last 12 months.
| Revenue | $7.11M |
|---|---|
| Revenue Growth (YoY) | +4456.78% |
| Gross Profit | $5.43M |
| Operating Income | -$61.38M |
| Pretax Income | -$57.98M |
| Net Income | -$58.17M |
| EBITDA | -$57.24M |
| Reported EPS (TTM) | -$1.78 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 46.82% of the $142.26M in total assets.
| Cash and Equivalents | $17.01M |
|---|---|
| Total Debt | $6.41M |
| Net Cash | $10.60M |
| Net Cash Per Share | $0.40 |
| Working Capital | -$8.32M |
| Shareholder Equity | $66.61M |
| Book Value Per Share | $2.55 |
| Tangible Book Value | $57.27M |
| Tangible Book Per Share | $2.19 |
| Total Assets | $142.26M |
| Total Liabilities | $66.35M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Operating Cash Flow | -$34.87M |
|---|---|
| FCF Per Share | -$1.27 |
| Depreciation and Amortization | $4.32M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -863.92%.
| Gross Margin | 76.47% |
|---|---|
| Operating Margin | -863.92% |
| Pretax Margin | -815.97% |
| Net Margin | -818.65% |
| EBITDA Margin | -805.63% |
Dividends and Yields
CTXR does not pay a dividend.
| Buyback Yield | -302.44% |
|---|---|
| Shareholder Yield | -302.44% |
Stock Splits
The last split was a 1-for-25 reverse split on Nov 26, 2024.
| Last Split Date | Nov 26, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Peer Position
Against 3 similar companies, CTXR has the 3rd highest P/S and the highest ROIC.
P/S RatioPeer median 8.2x
ROICPeer median -650.83%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -32.90%
| P/S Ratio | 1.9x vs 8.2x median |
|---|---|
| ROIC | -84.31% vs -650.83% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4456.77% vs -32.90% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CTXR
What is CTXR's market cap?
Citius Pharmaceuticals has a market cap of $14.69M. Its enterprise value, which adds debt and subtracts cash, is $4.09M.
How many shares of CTXR are outstanding?
Citius Pharmaceuticals has 26.17M shares outstanding. The count is up 137.76% from a year earlier.
Does CTXR pay a dividend?
No. Citius Pharmaceuticals does not pay a dividend.
How much debt does CTXR have?
Citius Pharmaceuticals has $6.41M of total debt and $17.01M of cash and equivalents, a net cash position of $10.60M.
CTXR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors